Page last updated: 2024-08-23

paclitaxel and Cancer of the Fallopian Tube

paclitaxel has been researched along with Cancer of the Fallopian Tube in 156 studies

Research

Studies (156)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's7 (4.49)18.2507
2000's51 (32.69)29.6817
2010's82 (52.56)24.3611
2020's16 (10.26)2.80

Authors

AuthorsStudies
Aoki, D; Chiyoda, T; Hirasawa, A; Iwasa-Inoue, N; Kataoka, F; Kobayashi, Y; Morisada, T; Nanki, Y; Nomura, H; Sakai, K; Yamagami, W; Yoshihama, T1
Bixel, K; Brady, MF; Burger, RA; Casey, AC; Cosgrove, C; duPont, NC; Enserro, D; Fujiwara, K; Monk, BJ; Moxley, K; Rubin, S; Soper, J; Tewari, KS; Thaker, P; Wahner Hendrickson, AE; Walker, JL1
Benjamin, L; Corr, BR; Culm-Merdek, K; Fu, S; Hamilton, EP; Mockbee, C; Moore, KN; Naumann, RW; Rosengarten, RD; Stagg, R; Wenham, RM; Youssoufian, H1
Bohart, RD; Goldstein, BH; Micha, JP; Rettenmaier, MA1
Jimi, T; Kaneda, M; Kitai, M; Matsuoka, K; Nagao, S; Shibutani, T; Shiozaki, T; Sudo, T; Suzuki, K; Yamaguchi, S; Yamamoto, K; Yano, H1
Aghajanian, C; Armstrong, DK; Bell-McGuinn, KM; Chen, A; Duska, LR; Fracasso, PM; Gordon, S; Gray, HJ; Guntupalli, SR; Hagemann, AR; Mathews, CA; Miller, A; Moore, KN; O'Cearbhaill, RE; O'Malley, D; Schilder, RJ; Walker, JL1
Iida, Y; Odajima, S; Okamoto, A; Saito, M; Tabata, J; Ueda, K; Yamada, K; Yanaihara, N; Yokomizo, R1
Chang, HK; Chang, SJ; Han, SS; Kim, DY; Kim, HS; Kim, J; Kim, S; Lee, JW; Lee, KH; Park, SJ; Park, SY; Shim, SH1
Burger, R; Coleman, RL; Handley, KF; Molin, GZD; Moore, KN; Sood, AK; Stagg, R1
Chang, SJ; Ji, YI; Kim, HS; Kim, JW; Kim, SY; Kwon, SH; Lee, EJ; Lee, M; Lee, SH; Lee, SJ; Park, S; Park, SJ; Roh, JW; Shim, SH; Song, T1
Chen, ZP; Jiang, J; Ni, C; Qian, XL; Zhang, M; Zhang, YQ; Zhu, HP; Zuo, Y1
Aghajanian, C; Banerjee, S; Berger, R; Boyd, AP; Christy-Bittel, J; Churruca, C; Cibula, D; Clamp, A; Coleman, RL; Colombo, N; Del Campo, JM; Drill, E; Grisham, RN; Hilpert, F; Kalbacher, E; Kristensen, G; Marth, C; Mirza, MR; Monk, BJ; Moore, KN; O'Malley, DM; Oehler, MK; Oza, AM; Pignata, S; Ray-Coquard, I; Romero, I; Sehouli, J; Vergote, I; Vuylsteke, P; Westermann, A1
Chosokabe, M; Deura, I; Kawamoto, H; Koike, J; Kondo, H; Kuji, S; Maeda, I; Migita, O; Ohara, T; Suzuki, N; Tozawa-Ono, A; Tsugawa, K1
Elit, L; Ethier, JL; Hirte, H; May, T; Petz, L; Poon, R; Speakman, J; Yao, X1
Backes, FJ; Bixel, K; Chen, M; Cohn, DE; Copeland, LJ; Cosgrove, C; Dzwigalski, K; Fowler, JM; Hays, J; Hill, K; O'Malley, D; Phelps, M; Poi, M; Salani, R; Wei, L1
Ikeda, T; Kaneda, M; Kondo, E; Maki, S; Nii, M; Nimura, R; Tabata, T; Yoshida, K1
Armstrong, DK; Ashfaq, R; Basen-Engquist, K; Brady, MF; Chan, JK; Coleman, RL; Davidson, SA; DiSilvestro, P; Fujiwara, K; Herzog, TJ; Huang, H; Kim, BG; Mannel, RS; O'Malley, DM; Rubin, SC; Sabbatini, P; Spirtos, NM; Tewari, KS; Walker, JL1
Bulsara, M; Codde, J; Coghlan, E; Cohen, PA; Koay, MHE; Leung, Y; MaGee, D; Meniawy, TM; Mohan, GR; Munro, A; Nichols, CB; Salfinger, SG; Stewart, CJ; Tan, A; Tan, J1
Celebi, K; Kaban, A; Saip, P; Salihoglu, Y; Sozen, H; Topuz, S1
Aoki, D; Hashimoto, S; Hirano, T; Hirasawa, A; Iwasa, N; Kataoka, F; Makabe, T; Nanki, Y; Nomura, H; Sakai, K; Yamagami, W; Yoshihama, T1
Bun, S; Ebata, T; Fujiwara, Y; Kato, T; Kodaira, M; Shimizu, C; Shimoi, T; Shimomura, A; Tamura, K; Yonemori, K; Yoshida, H; Yunokawa, M1
Mandai, M; Matsumura, N; Murakami, K; Nakai, H; Suzuki, A; Takaya, H; Tobiume, T1
Becker, DA; Bevis, KS; Leath, CA; Smith, BQ; Walters-Haygood, CL1
Kruitwagen, RF; Lalisang, RI; Sonke, GS; Timmermans, M; Van de Vijver, KK; van der Aa, MA; Witteveen, PO1
Begum, S; Jakes, A; Lane, G; Mehra, G; Nath, R; Polson, A; Rajkumar, S; Sayasneh, A1
Aghajanian, C; Bonebrake, AJ; Dewdney, SB; Johnston, CM; Kauderer, JT; Monk, BJ; Moxley, KM; Secord, AA; Ueland, FR1
Aghajanian, C; Bender, DP; Carlson, JW; Crane, EK; Darus, CJ; Makker, V; Mannel, RS; Matulonis, UA; Mutch, DG; Sill, MW1
Bakrin, N; Gladieff, L1
Akladios, C; Alfonsi, P; Bakrin, N; Ballester, M; Bendifallah, S; Bolze, PA; Bonnet, F; Bourgin, C; Chabbert-Buffet, N; Collinet, P; Courbiere, B; Daraï, E; De la Motte Rouge, T; Devouassoux-Shisheboran, M; Falandry, C; Ferron, G; Fournier, L; Gladieff, L; Golfier, F; Gouy, S; Guyon, F; Huchon, C; Lambaudie, E; Lavoue, V; Leary, A; Leblanc, E; Lecuru, F; Lefrere-Belda, MA; Lemoine, A; Narducci, F; Ouldamer, L; Pautier, P; Planchamp, F; Pouget, N; Ray-Coquard, I; Rousset-Jablonski, C; Senechal-Davin, C; Thomassin-Naggara, I; Touboul, C; Uzan, C; You, B1
Bamias, A; Colombo, N; Covens, A; Del Campo, JM; Kroep, JR; Ma, H; Marth, C; Meier, W; Monk, BJ; O'Malley, DM; Park, SY; Pickett, CA; Raza Mirza, M; Scambia, G; Van Calster, B; Vergote, I; Wenham, RM1
Blaakaer, J; Christiansen, T; Iversen, LH; Mikkelsen, MS; Petersen, LK1
Armstrong, DK; Coleman, RL; Phillips, M; Weil, SC; White, AJ1
Apte, SM; Bou Zgheib, N; Gonzalez-Bosquet, J; Judson, PL; Lancaster, JM; Roberts, WS; Teefey, P; Wenham, RM1
Abaid, LN; Brown, JV; Goldstein, BH; Lopez, KL; Mendivil, AA; Micha, JP; Rettenmaier, MA2
Khemapech, N; Lertkhachonsuk, R; Oranratanaphan, S; Termrungruanglert, W; Vasurattana, A1
Dhillon, S1
Bookman, MA; Brady, MF; Burger, RA; Kong, G; Nguyen, HP; Rhee, J; Sovak, MA1
Aoki, D; Isonishi, S; Jobo, T; Katsumata, N; Kimura, E; Kodama, S; Michimae, H; Ochiai, K; Sugiyama, T; Takahashi, F; Terauchi, F; Yasuda, M1
Bae, DS; Choi, CH; Kim, BG; Kim, HJ; Kim, MK; Kim, TJ; Lee, JW; Lee, YY; Park, JY; Yoon, A1
Awtrey, CS; Battelli, C; Buss, MK; Campo, M; Konstantinopoulos, PA1
Dowlati, A; Eaton, S; Frasure, H; Fu, P; Fusco, N; Schwandt, A; von Gruenigen, VE; Waggoner, S; Wenham, RM; Wright, JJ1
Cheewakriangkrai, C; Khunamornpong, S; Kietpeerakool, C; Phongsaranantakul, S; Sribanditmongkol, N; Srisomboon, J1
Banerjee, S; Clamp, A; Dawson-Athey, L; Earl, H; Feeney, A; Hall, G; Hall, M; James, L; Kaye, SB; Khan, I; Kristeleit, R; Lawrence, C; Ledermann, JA; McNeish, IA; Persic, M; Raja, F; Webber, L1
Andrade, C; Clark, RM; del Carmen, MG; Esselen, KM; Foley, OW; Hinchcliff, EM; Horowitz, NS; Rauh-Hain, JA; Vargas, RJ; Winograd, D1
Katsumata, N1
Böhm, S; Brockbank, E; Cook, LS; Dowe, T; Ennis, D; Faruqi, A; Fitzpatrick, A; Gilks, CB; Jeyarajah, A; Le, ND; Lockley, M; Said, I; Santos, JL; Singh, N; Tinker, AV1
Beijnen, JH; Harms, E; Marchetti, S; Mergui-Roelvink, MW; Rehorst, H; Schellens, JH; Sonke, GS; Steeghs, N; van der Noll, R1
Alexander, H; Banerjee, S; Barton, D; Bodla, S; Georgiou, A; Gore, M; Kaye, S; McLachlan, J; Nobbenhuis, M; Seifert, H1
Burger, RA; Cohn, DE; Duska, LR; Java, JJ1
Fernandez, RO; Iniesta, MD; Lu, KH; Malpica, A; Patrono, MG; Ramirez, PT; Salvo, G1
Bidziński, M; Bjørge, L; Colombo, N; de Gregorio, N; Del Campo, JM; Denison, U; du Bois, A; Harter, P; Heubner, M; Hilpert, F; Kristensen, G; Lortholary, A; Malander, S; Meier, W; Merger, M; Minarik, T; Mirza, MR; Nicoletto, MO; Ottevanger, P; Pfisterer, J; Pignata, S; Ray-Coquard, I; Reuss, A; Sailer, MO; Scambia, G; Sevin, E; Vergote, I1
Chaithongwongwatthana, S; Yanaranop, M1
Alpert, Y; Bruchim, I; Fishman, A; Piura, E; Sade, D; Weeg, N1
Chang, WP; Chang, Y; Chang, YH; Chuang, CM; Lee, WH; Lu, CH; Yen, MS1
Akkar, OB; Karadayi, K; Karakus, S; Kurt, A; Ugurlu, GP; Yanik, A; Yildiz, C1
Chi, DS; Gardner, GJ; Long Roche, K; Mueller, JJ; O'Cearbhaill, RE; Schlappe, BA; Sonoda, Y; Zivanovic, O1
Aviki, E; Berkowitz, R; Clark Sisodia, R; Davis, M; Del Carmen, M; Horowitz, N; Muto, M; Rauh-Hain, JA; Schorge, J; Worley, M1
Kamura, T; Kasamatsu, T; Kawana, K; Kobayashi, H; Konishi, I; Nakamura, K; Nakanishi, T; Onda, T; Saito, M; Saito, T; Satoh, T; Takano, M; Takehara, K; Takeshima, N; Ushijima, K; Wakabayashi, M; Watanabe, Y; Yaegashi, N; Yokota, H; Yoshikawa, H1
Bun, S; Ebata, T; Fujiwara, Y; Hayashi, Y; Kato, T; Kodaira, M; Makino, Y; Shimizu, C; Shimoi, T; Shimomura, A; Tamura, K; Yonemori, K; Yunokawa, M1
Bamias, A; Chmielowska, E; Colombo, N; Davidenko, I; DeCensi, A; Gadducci, A; González-Martín, A; Hegg, R; Joly, F; Korach, J; Martin, N; Mendiola, C; Oza, AM; Pautier, P; Robb, S; Selle, F; Zamagni, C; Zvirbule, Z1
Bun, S; Ebata, T; Fujiwara, Y; Kato, T; Kodaira, M; Shimizu, C; Shimoi, T; Shimomura, A; Tamura, K; Yonemori, K; Yunokawa, M1
Lengyel, E; Onujiogu, N; Yamada, SD1
Aghajanian, CA; DeRosa, FA; Gerst, SR; Hensley, ML; Konner, J; Sabbatini, PJ; Schilder, RJ; Spriggs, DR; Tew, WP1
Aragon-Ching, JB; Dahut, WL; Desai, N; Figg, WD; Gardner, ER; Hawkins, MJ; Jones, J; Scripture, CD; Sparreboom, A1
Aikins, JK; Allievi, C; Bookman, MA; Darcy, KM; DeGeest, K; Egorin, MJ; Mannel, RS; Morgan, MA; Rose, PG; Sill, MW1
Bamias, A; Bozas, G; Dimopoulos, MA; Grimani, I; Lainakis, G; Lianos, E; Papadimitriou, CA; Peitsidis, P; Rodolakis, A; Vlahos, G1
Adler, L; O'Malley, D; Sabbatini, P; Secord, AA; Sill, MW1
Itamochi, H; Kanamori, Y; Kawaguchi, W; Kigawa, J; Oishi, T; Sato, S; Shimada, M; Terakawa, N1
Atkinson, T; Horowitz, NS; Krag, KJ; Krasner, CN; Lee, H; Matulonis, UA; Penson, RT1
Alberts, DS; Liu, PY; Markman, M; Robinson, WR; Smith, HO; Tiersten, AD; Wilczynski, SP1
Fukuda, H; Hatae, M; Iwasaka, T; Kamura, T; Kobayashi, H; Konishi, I; Nakanishi, T; Onda, T; Shibata, T; Yoshikawa, H1
Alvarez, RD; Berry, E; Buttin, BM; Lurain, JR; Matthews, KS; Schink, J; Singh, DK1
Asmar, L; Boehm, KA; Crozier, M; Encarnacion, C; Hancock, K; Messing, MJ; Teneriello, MG; Tseng, PC; Williams, A1
Argenta, PA; Geller, M; Ivy, JJ; Jonson, AL; Pierson, SM1
Andreadis, C; Aravantinos, G; Economopoulos, T; Fountzilas, G; Macheras, A; Papatsibas, G; Papaxoinis, G; Pectasides, D; Pectasides, E; Pliarchopoulou, K1
Eno, ML; Im, DD; Matsuo, K; Rosenshein, NB; Sood, AK1
Groe, R; Grothey, A; Kantelhardt, EJ; Kegel, T; Koelbl, H; Mueller, LP; Schmoll, HJ; Seliger, G; Strauss, HG; Thomssen, C1
Bougnoux, P; Carrasco, AT; Fumoleau, P; Joly, F; Kerbrat, P; Lhommé, C; Pautier, P; Petit, T; Ringeisen, F; Rixe, O1
Fracasso, PM; Garcia, AA; Knight, D; Mannel, RS; Muggia, F; Sill, MW; Swensen, R; Tiersten, AD; Warshal, DP1
Adamus, G; Bodurka, DC; Liu, J; Raghunath, A; Schiffman, JS1
Blank, SV; Chen, HX; Christos, P; Curtin, JP; Goldman, N; Liebes, L; Muggia, FM; Runowicz, CD; Sparano, JA1
Ahn, EH; Eno, ML; Im, DD; Matsuo, K; Rosenshein, NB; Shahzad, MM; Sood, AK1
Aoki, D; Aotani, E; Fujiwara, K; Hamano, T; Katsumata, N; Kigawa, J; Nagao, S; Sugiyama, T; Suzuki, M; Takeuchi, M; Yoshikawa, H1
Clamp, AR; Evans, S; Griffiths, RW; Hasan, J; Jayson, GC; Kumaran, GC; Mitchell, CL; Welch, RS; Zee, YK1
Ishikawa, M; Komiyama, M; Komiyama, S; Kurahashi, T; Mikami, M; Tanaka, K; Udagawa, Y1
Coleman, RL; Degeest, K; Fujiwara, K; Greer, B; Mannel, RS; Morgan, MA; Rubin, SC; Sill, MW; Waggoner, S; Walker, JL; Yamada, SD1
Arimoto, T; Kawana, K; Nakagawa, S; Oda, K; Taketani, Y; Yasugi, T1
Azodi, M; Baker, L; Husband, A; Kelly, MG; Mor, G; O'Malley, DM; Rutherford, TJ; Schwartz, PE1
Abaid, LN; Brown, JV; Goldstein, BH; Lopez, KL; Micha, JP; Rettenmaier, MA1
Brady, WE; Coleman, RL; Hoffman, JS; Lentz, SS; McMeekin, DS; Rose, PG; Shahin, MS; Soper, JT1
Hwang, JH; Lee, JK; Lee, KW; Lee, NW; Shin, BK; Song, SH1
Hyde, J; Landrum, LM; Mannel, RS; McMeekin, DS; Moore, KN; Walker, JL1
Changchien, CC; Huang, CC; Huang, HY; Lin, H; Ou, YC; Tseng, CW1
Debernardo, RL; Dizon, DS; Duska, LR; Eisenhauer, EL; Fracasso, PM; Gould, N; Mannel, RS; Rubin, SC; Sill, MW; Yamada, SD1
Griffin, CL; Hirte, H; Ledermann, JA; Parmar, MK; Qian, W; Raja, FA; Swart, AM1
Burkholder, TL; Chen, MD; Gill, JF; Gordon, AN; Hines, J; Homesley, HD; Janicek, MF; Lim, PC; McMeekin, S; Obasaju, CK; Orlando, M; Tai, DF; Teneriello, M; Vaccarello, L; Wang, Y; Zhao, L1
Ota, T; Takeshima, N; Takizawa, K1
Fujiwara, K; Goto, T; Hasegawa, K; Iwasa, N; Kurosaki, A; Nagao, S; Nishikawa, T; Ohishi, R1
Armstrong, DK; Disilvestro, P; Fracasso, PM; Gould, N; Huang, H; Mannel, RS; Sill, MW; Thaker, PH; Waggoner, S; Walker, JL; Wenzel, L; Yamada, SD1
Brown, JV; Buck, M; Chambers, SK; Covens, A; Davy, M; Ghatage, P; Hansen, VL; Karlan, BY; Leath, CA; Nagarkar, RV; Nguyen, H; Oza, AM; Pippitt, CH; Provencher, DM; Richardson, GE; Stepan, DE; Sun, YN; Tassoudji, M; Vergote, IB; Weinreich, DM1
Itamochi, H; Kigawa, J; Kitada, F; Minagawa, Y; Okada, M; Sato, S; Shimada, M1
Abu Shahin, N; Alberts, DS; Chambers, SK; Chow, HH; Clouser, MC; Cohen, JL; Cragun, JM; Cui, H; Hatch, KD; Janicek, MF; Laughren, C; Wright, HM1
Gallagher, CJ; Jeyarajah, A; Ledermann, JA; McCormack, M; McDonald, N; McNeish, I; Mould, T; Olaitan, A; Oram, D; Orphanos, G; Reynolds, K; Saha, A; Shepherd, J; Varughese, M; Wilson, P1
Gawrychowski, K; Jeske, W; Smiertka, W1
Aghajanian, C; Barlin, JN; Bell-McGuinn, KM; Bou Zgheib, N; Chi, DS; Dao, F; Ferguson, SE; Hensley, ML; Konner, J; Sabbatini, PJ; Tew, WP1
Bristow, RE; Chang, SJ; Ryu, HS1
Campos, S; Esselen, KM; Growdon, W; Horowitz, NS; Krasner, C; Rodriguez, N1
Ho, ES; Hsu, ST; Ke, YM; Lu, CH; Tsai, CP; Wang, RC1
Armstrong, DK; DiSilvestro, PA; Fracasso, PM; Gould, N; Mannel, RS; Sill, MW; Thaker, PH; Waggoner, SE; Walker, JL; Yamada, SD1
Boaz, M; Golan, A; Levy, T; Menczer, J; Shem, EB; Weiser, R1
Antsaklis, A; Bamia, C; Bamias, A; Dimopoulos, MA; Haidopoulos, D; Kakoyianni, K; Kostouros, E; Rodolakis, A; Thomakos, N; Vlahos, G; Zagouri, F1
Chu, P; Ghatage, P; Glaze, S; Nation, J; Nelson, G; Teitelbaum, L1
Bamba, M; Fujimoto, Y; Kaneko, C; Kobayashi, TK; Moritani, S; Urabe, M1
Alberts, DS; Glass, T; Goodwin, JW; Hatch, KD; Markman, M; Smith, HO; Taylor, SA; Weiss, GR1
Alberts, D; Alvarez, RD; Copeland, LJ; Jiang, C; Liu, PY; Markman, M; Monk, B; Wilczynski, S1
Belinson, J; Kulp, B; Markman, M; Peterson, G; Webster, K; Zanotti, K2
Bilezikci, B; Demirhan, B; Erkanli, S; Haberal, A; Kuscu, E; Oktem, M1
Belinson, J; Escobar, PF; Markman, M; Rose, P; Webster, K; Zanotti, K1
A'Hern, R; Cole, C; Everard, M; Gibbens, I; Gore, M; Hall, G; Harries, M; Jenkins, A; Kaye, S; Moss, C; Perren, T; Pizzada, O; Shah, R1
Birk, CL; Brown, JV; Goldstein, BH; Graham, C; Mattison, J; Micha, JP; Rettenmaier, MA1
Aghajanian, C; Anderson, S; Brown, JV; Dizon, D; Dupont, J; Eisenfeld, AJ; Jacobs, A; Mehdi, A; Peters, WA; Rivkin, S; Sabbatini, P; Spriggs, D1
Kietpeerakool, C; Srisomboon, J; Suprasert, P1
Asai, S; Dokoh, J; Ishikawa, M; Komiyama, S; Mikami, M; Tsuji, H1
Acikalin, MF; Ozalp, S; Peker, B; Yalcin, OT1
Carvalho, FM; Carvalho, JP; Feher, O; Maluf, FC; Schütz, FA1
Horowitz, NS; Krasner, CN; Lee, SI; Oliva, E; Roche, M; Supko, JG1
Campos, S; Duska, LR; Falke, R; Krasner, CN; Lee, H; Matulonis, UA; Penson, RT; Roche, M; Seiden, MV; Smith, LM1
Altundag, OB; Gungor, T; Mollamahmutoglu, L; Ustunyurt, E1
Fusco, N; Greer, BE; Horowitz, IR; Markman, M; Rose, PG1
Boggess, JF; Brady, MF; Burger, RA; Clarke-Pearson, DL; Hanly, M; Lee, RB; Mannel, R; Spriggs, DR; Vaccarello, L1
Aydin, Y; Cicin, I; Eralp, Y; Ozluk, Y; Saip, P; Selam, M; Topuz, E; Topuz, S1
Fukuda, H; Kamura, T; Konishi, I; Matsumoto, K; Onda, T; Sato, A; Shibata, T; Yoshikawa, H1
Fang, SH; Gao, YL; Yu, AJ1
Edwards, CL; Fromm, GL; Kavanagh, JJ; Kudelka, AP; Mante, R; Tresukosol, D1
Cai, S; Fan, J; Tang, J1
Francis, P; Hakes, T; Hoskins, W; Markman, M; Rowinsky, E; Schneider, J1
Loizzi, P; Nappi, L; Nappi, R; Resta, L1
Belinson, J; Fluellen, L; Fusco, N; Horowitz, IR; Jones, E; Kennedy, A; Kulp, B; Markman, M; McGuire, WP; Peterson, G; Rose, PG; Webster, K1
Brady, MF; Hanjani, P; Markman, M; Rubin, SC; Spirtos, NM1
Belinson, J; Hurteau, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Sutton, G; Webster, K1
Atkinson, EN; Guedes, Ed; Kavanagh, JJ; Kudelka, AP; Nelson-Taylor, T; Rogers, R; Sittisomwong, T; Steger, M; Verschraegen, CF; Vincent, M1
Fowler, JM; Greer, BE; Horowitz, IR; McGuire, WP; Rodriguez, M; Rose, PG; Waggoner, S1
Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K3
Barakat, RR; Cohen, R; Gemignani, ML; Hensley, ML; Saigo, PE; Venkatraman, E1
Adolph, A; Biem, S; Khan, K; Le, T1
Allen, D; Davison, J; Gates, P; Neesham, D; Planner, R; Prince, HM; Quinn, M; Rischin, D1
Cormio, G1
Shao, H1
Gadducci, A1
Newton, HB; Santi, M; Stevens, C1
Allen, M; Gibbs, DD; Gore, ME; Johnston, SR; Pyle, L; Vaughan, M; Webb, A1
Buekers, T; Buller, RE; Horowitz, JA; Karlan, BY; Kreienberg, R; Pegram, M; Petrauskas, S; Runnebaum, IB; Shahin, M; Slamon, D1

Reviews

9 review(s) available for paclitaxel and Cancer of the Fallopian Tube

ArticleYear
Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review.
    Critical reviews in oncology/hematology, 2021, Volume: 162

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Quality of Life

2021
[Malignant epithelial ovarian cancer: Role of intra peritoneal chemotherapy and hyperthermic intra peritoneal chemotherapy (HIPEC): Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian can
    Gynecologie, obstetrique, fertilite & senologie, 2019, Volume: 47, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Fallopian Tube Neoplasms; Female; France; Humans; Hyperthermia, Induced; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quality of Life; Societies, Medical

2019
Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2013, Volume: 27, Issue:4

    Topics: Adult; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Evidence-Based Medicine; Fallopian Tube Neoplasms; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A

2013
Dose-dense approaches to ovarian cancer treatment.
    Current treatment options in oncology, 2015, Volume: 16, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis

2015
Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): A comprehensive review.
    Gynecologic oncology, 2015, Volume: 139, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma in Situ; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Humans; Incidence; Mutation; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Platinum Compounds; Salpingectomy

2015
Primary clear cell carcinoma of a paratubal cyst: a case report with literature review.
    The Australian & New Zealand journal of obstetrics & gynaecology, 2011, Volume: 51, Issue:3

    Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fallopian Tube Neoplasms; Female; Humans; Keratins; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Parovarian Cyst; Salpingectomy

2011
Management of advanced-stage primary carcinoma of the fallopian tube: case report and literature review.
    European journal of gynaecological oncology, 2003, Volume: 24, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta, Thoracic; Appendectomy; Cisplatin; Cystadenocarcinoma, Serous; Diagnosis, Differential; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Hysterectomy; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Omentum; Ovariectomy; Paclitaxel; Pelvic Neoplasms; Second-Look Surgery

2003
Mixed serous and endometrioid carcinoma of the fallopian tube: a case report with literature review.
    European journal of gynaecological oncology, 2005, Volume: 26, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Cyclophosphamide; Cystadenocarcinoma, Serous; Fallopian Tube Neoplasms; Female; Gynecologic Surgical Procedures; Humans; Mixed Tumor, Malignant; Neoplasm Staging; Paclitaxel; Treatment Outcome

2005
Current management of fallopian tube carcinoma.
    Current opinion in obstetrics & gynecology, 2002, Volume: 14, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Ovariectomy; Paclitaxel

2002

Trials

78 trial(s) available for paclitaxel and Cancer of the Fallopian Tube

ArticleYear
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
    Gynecologic oncology, 2022, Volume: 164, Issue:2

    Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Asian; Bevacizumab; Black or African American; Carboplatin; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Ethnicity; Fallopian Tube Neoplasms; Female; Hispanic or Latino; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Proportional Hazards Models; Survival Rate; White People

2022
Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 08-10, Volume: 40, Issue:23

    Topics: Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies; RNA; Tumor Microenvironment; Vascular Endothelial Growth Factor A

2022
A phase II, open-label, non-randomized, prospective study assessing paclitaxel, carboplatin and metformin in the treatment of advanced stage ovarian carcinoma.
    Journal of gynecologic oncology, 2023, Volume: 34, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies

2023
A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.
    Gynecologic oncology, 2020, Volume: 156, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Progression-Free Survival

2020
Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
    Gynecologic oncology, 2020, Volume: 157, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Progression-Free Survival; Survival Analysis

2020
Reduction of cycles of neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian or primary peritoneal cancer (ROCOCO): study protocol for a phase III randomized controlled trial.
    BMC cancer, 2020, May-06, Volume: 20, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Case-Control Studies; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Survival Rate; Young Adult

2020
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 11-10, Volume: 38, Issue:32

    Topics: Adult; Aged; Benzimidazoles; Cystadenocarcinoma, Serous; Doxorubicin; Fallopian Tube Neoplasms; Female; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Progression-Free Survival; Protein Kinase Inhibitors; Topotecan; Young Adult

2020
Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer.
    Gynecologic oncology, 2021, Volume: 162, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Genital Neoplasms, Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Quinolines

2021
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2017, Volume: 18, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Young Adult

2017
Utilization of an Alternative Docetaxel-based Intraperitoneal Chemotherapy Regimen in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma: A Continued Need for Ovarian Cancer Patients.
    American journal of clinical oncology, 2019, Volume: 42, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome

2019
A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.
    Gynecologic oncology, 2018, Volume: 151, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Fallopian Tube Neoplasms; Female; Humans; Hydrazines; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2018
A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecologic oncology, 2019, Volume: 152, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Protein Kinase Inhibitors; Pyridines

2019
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
    The Lancet. Oncology, 2019, Volume: 20, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Double-Blind Method; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Recombinant Fusion Proteins; Salvage Therapy; Survival Rate

2019
Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
    Gynecologic oncology, 2013, Volume: 129, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids

2013
A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
    Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Consolidation Chemotherapy; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Intention to Treat Analysis; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Severity of Illness Index; Survival Analysis

2013
Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.
    Gynecologic oncology, 2013, Volume: 131, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Neoplasms, Glandular and Epithelial; Observer Variation; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Radiography; Single-Blind Method

2013
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Proportional Hazards Models

2013
Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014, Volume: 22, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Benzimidazoles; Carboplatin; Dexamethasone; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Morpholines; Nausea; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Vomiting; Young Adult

2014
Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
    Investigational new drugs, 2014, Volume: 32, Issue:4

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Niacinamide; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Sorafenib

2014
A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Disease-Free Survival; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Quinazolines; Retroperitoneal Neoplasms

2014
Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.
    British journal of cancer, 2015, Jul-28, Volume: 113, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease Progression; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Salvage Therapy; Treatment Failure

2015
Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236).
    Gynecologic oncology, 2015, Volume: 139, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Bevacizumab; Body Mass Index; CA-125 Antigen; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Obesity; Ovarian Neoplasms; Paclitaxel; Patient Readmission; Peritoneal Neoplasms; Risk Factors; Time Factors

2015
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
    The Lancet. Oncology, 2016, Volume: 17, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cytoreduction Surgical Procedures; Diarrhea; Disease Progression; Disease-Free Survival; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Indoles; Intention to Treat Analysis; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Response Evaluation Criteria in Solid Tumors; Thrombocytopenia; Young Adult

2016
Intravenous versus oral dexamethasone for prophylaxis of paclitaxel-associated hypersensitivity reaction in patients with primary ovarian, fallopian tube and peritoneal cancer: A double-blind randomized controlled trial.
    Asia-Pacific journal of clinical oncology, 2016, Volume: 12, Issue:3

    Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Animals; Antineoplastic Agents, Phytogenic; Dexamethasone; Double-Blind Method; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2016
High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer-A Phase 2 Cohort Study.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2016, Volume: 26, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Cohort Studies; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Taxoids

2016
Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Gr
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 64

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Analysis

2016
Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2017, Volume: 27, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Young Adult

2017
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer.
    Gynecologic oncology, 2008, Volume: 110, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Chemotherapy, Adjuvant; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2008
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jul-01, Volume: 14, Issue:13

    Topics: Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Cross-Over Studies; Fallopian Tube Neoplasms; Female; Humans; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Solvents

2008
Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group.
    Gynecologic oncology, 2008, Volume: 110, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Drug Interactions; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyglutamic Acid

2008
A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.
    Gynecologic oncology, 2008, Volume: 111, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyglutamic Acid

2008
Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors.
    Gynecologic oncology, 2009, Volume: 112, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Genital Neoplasms, Female; Humans; Mixed Tumor, Mullerian; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Quality of Life

2009
Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009.
    Gynecologic oncology, 2009, Volume: 112, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2009
Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206.
    Gynecologic oncology, 2009, Volume: 113, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Middle Aged; Mixed Tumor, Mullerian; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Patient Compliance; Peritoneal Neoplasms

2009
Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Mar-20, Volume: 27, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Phytogenic; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quality of Life

2009
Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2009, Volume: 19, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Risk Factors; Taxoids; Treatment Outcome; Young Adult

2009
Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
    Gynecologic oncology, 2010, Volume: 116, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gefitinib; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines

2010
A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Gynecologic oncology, 2010, Volume: 118, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Polyethylene Glycols; Recombinant Proteins

2010
Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment.
    Gynecologic oncology, 2010, Volume: 119, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Fallopian Tube Neoplasms; Female; Gene Amplification; Genes, erbB-1; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines; Young Adult

2010
A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study.
    Gynecologic oncology, 2011, May-01, Volume: 121, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Young Adult

2011
Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Isoflavones; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum Compounds; Taxoids; Treatment Failure; Treatment Outcome

2011
A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Gynecologic oncology, 2011, Volume: 122, Issue:1

    Topics: Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Nanoparticles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2011
Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer.
    Gynecologic oncology, 2011, Volume: 122, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheterization; Cisplatin; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2011
Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study.
    Gynecologic oncology, 2011, Volume: 123, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2011
Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer.
    British journal of cancer, 2011, Sep-27, Volume: 105, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines; Survival Rate; Treatment Outcome

2011
Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.
    Gynecologic oncology, 2011, Volume: 123, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Induction Chemotherapy; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Young Adult

2011
Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2012, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Drug Administration Schedule; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome

2012
A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncol
    Gynecologic oncology, 2012, Volume: 125, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2012
Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Feb-01, Volume: 30, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Recombinant Fusion Proteins; Survival Analysis

2012
Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, May-01, Volume: 18, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Injections, Intraperitoneal; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Pemetrexed; Peritoneal Neoplasms; Prognosis; Survival Rate; Tissue Distribution

2012
A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic
    Gynecologic oncology, 2012, Volume: 127, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids

2012
Increased incidence of severe gastrointestinal events with first-line paclitaxel, carboplatin, and vorinostat chemotherapy for advanced-stage epithelial ovarian, primary peritoneal, and fallopian tube cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2013, Volume: 23, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Hydroxamic Acids; Incidence; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Survival Rate; Vorinostat

2013
Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial.
    Gynecologic oncology, 2003, Volume: 88, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2003
Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jul-01, Volume: 21, Issue:13

    Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome

2003
Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer.
    Gynecologic oncology, 2003, Volume: 90, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel

2003
Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers.
    Gynecologic oncology, 2004, Volume: 92, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2004
A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer.
    British journal of cancer, 2004, Aug-16, Volume: 91, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Lung; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome

2004
Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer.
    Gynecologic oncology, 2004, Volume: 94, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects

2004
Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Nov-15, Volume: 22, Issue:22

    Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyglutamic Acid; Taxoids

2004
Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen.
    Gynecologic oncology, 2006, Volume: 103, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Mixed Tumor, Mullerian; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan

2006
Paclitaxel and carboplatin therapy in stage I fallopian tube carcinoma.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2006, Volume: 95, Issue:2

    Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Second-Look Surgery

2006
Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
    Gynecologic oncology, 2007, Volume: 104, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols

2007
Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-01, Volume: 25, Issue:28

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Analysis

2007
Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602.
    Japanese journal of clinical oncology, 2008, Volume: 38, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Peritoneal Neoplasms

2008
[A clinical report of refractory carcinoma of ovary and fallopian tube treated with taxol].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 1995, Volume: 17, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Cystadenocarcinoma, Serous; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Remission Induction

1995
Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Infusions, Parenteral; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects

1995
Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Salvage Therapy; Treatment Failure

1998
Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:8

    Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate

1998
Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.
    Gynecologic oncology, 1998, Volume: 70, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carboplatin; Cisplatin; Cystadenocarcinoma, Papillary; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Ifosfamide; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

1998
Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:14

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Statistics, Nonparametric; Survival Analysis; Taxoids

2000
Phase I study of paclitaxel, carboplatin, and increasing days of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Etoposide; Fallopian Tube Neoplasms; Female; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Thrombocytopenia

2000
Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
    Gynecologic oncology, 2000, Volume: 78, Issue:3 Pt 1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Doxorubicin; Drug Carriers; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Erythema; Fallopian Tube Neoplasms; Female; Foot Dermatoses; Hand Dermatoses; Humans; Liposomes; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Stomatitis; Stroke Volume

2000
Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.
    Gynecologic oncology, 2000, Volume: 79, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Carboplatin; Cisplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan

2000
Paclitaxel-based chemotherapy in carcinoma of the fallopian tube.
    Gynecologic oncology, 2001, Volume: 80, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Survival Rate

2001
Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-01, Volume: 19, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Docetaxel; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids

2001
Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.
    Gynecologic oncology, 2001, Volume: 81, Issue:2

    Topics: Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan

2001
A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer.
    British journal of cancer, 2002, May-06, Volume: 86, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Liposomes; Middle Aged; Mixed Tumor, Mullerian; Ovarian Neoplasms; Paclitaxel; Treatment Outcome

2002
A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
    Cancer gene therapy, 2002, Volume: 9, Issue:7

    Topics: Adenoviridae; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Carboplatin; Cohort Studies; Combined Modality Therapy; DNA, Viral; Enzyme-Linked Immunosorbent Assay; Fallopian Tube Neoplasms; Female; Genes, p53; Genetic Therapy; Humans; Mutation; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Tomography, X-Ray Computed; Transgenes

2002

Other Studies

69 other study(ies) available for paclitaxel and Cancer of the Fallopian Tube

ArticleYear
Prospective feasibility study of neoadjuvant dose-dense paclitaxel plus carboplatin with bevacizumab therapy followed by interval debulking surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer patients.
    International journal of clinical oncology, 2022, Volume: 27, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cytoreduction Surgical Procedures; Fallopian Tube Neoplasms; Fallopian Tubes; Feasibility Studies; Female; Humans; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Prospective Studies

2022
Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study.
    International journal of clinical oncology, 2020, Volume: 25, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Peritoneal Neoplasms; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies

2020
A simple method of quantifying chemotherapy-induced peripheral neuropathy using PainVision PS-2100
    Asia-Pacific journal of clinical oncology, 2020, Volume: 16, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fallopian Tube Neoplasms; Female; Humans; Incidence; Japan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pain; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Pilot Projects; Risk Assessment; Risk Factors; Skin; Young Adult

2020
Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study.
    Journal of gynecologic oncology, 2020, Volume: 31, Issue:2

    Topics: Adult; Aged; Carboplatin; Cohort Studies; Doxorubicin; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Progression-Free Survival; Republic of Korea; Retrospective Studies

2020
Responses of metastatic primary fallopian tube carcinoma to pembrolizumab and nab-paclitaxel: A case report.
    Medicine, 2020, Jul-10, Volume: 99, Issue:28

    Topics: Adult; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Fallopian Tube Neoplasms; Female; Humans; Paclitaxel

2020
Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report.
    Japanese journal of clinical oncology, 2021, Mar-03, Volume: 51, Issue:3

    Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Unknown Primary; Paclitaxel; Salpingo-oophorectomy

2021
Prognostic Benefit of ≥6 Cycles of Neoadjuvant Chemotherapy for Advanced Ovarian, Tubal, and Peritoneal Cancers.
    Anticancer research, 2021, Volume: 41, Issue:8

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fallopian Tube Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies

2021
Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2017, Volume: 27, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cohort Studies; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies

2017
Poor Prognostic Factors in Patients Undergoing Surgery After Neoadjuvant Chemotherapy for Ovarian, Tubal, or Peritoneal Cancer.
    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2017, Volume: 39, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Turkey

2017
Efficacy and safety of dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube or peritoneal cancer.
    Japanese journal of clinical oncology, 2017, Nov-01, Volume: 47, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies

2017
The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2017, Volume: 27, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies

2017
Efficacy of weekly administration of paclitaxel and carboplatin for advanced ovarian cancer patients with poor performance status.
    International journal of clinical oncology, 2018, Volume: 23, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate

2018
Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer.
    Gynecologic oncology, 2018, Volume: 150, Issue:3

    Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Fallopian Tube Neoplasms; Female; Humans; Length of Stay; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Postoperative Complications; Survival Rate; Time Factors

2018
Prognostic implications of histological tumor regression (Böhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.
    Gynecologic oncology, 2018, Volume: 151, Issue:2

    Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Chemotherapy, Adjuvant; Cohort Studies; Cystadenocarcinoma, Serous; Fallopian Tube Neoplasms; Female; Humans; Membrane Proteins; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Regression Analysis; Retrospective Studies; Survival Rate

2018
Management of epithelial cancer of the ovary, fallopian tube, primary peritoneum. Long text of the joint French clinical practice guidelines issued by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY, endorsed by INCa. (Part 2: systemic, intraperitoneal treatment, e
    Journal of gynecology obstetrics and human reproduction, 2019, Volume: 48, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Bevacizumab; Carboplatin; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Female; Fertility Preservation; France; Humans; Hyperthermia, Induced; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2019
Morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with carboplatin used for ovarian, tubal, and primary peritoneal cancer.
    Journal of surgical oncology, 2019, Volume: 120, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Fallopian Tube Neoplasms; Female; Humans; Hyperthermia, Induced; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies

2019
Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers.
    American journal of obstetrics and gynecology, 2013, Volume: 208, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Drug Administration Schedule; Drug Tolerance; Fallopian Tube Neoplasms; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome

2013
Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:3

    Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Phosphatidylcholines; Polyethylene Glycols; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate

2013
Safety and outcome of patients treated with a modified outpatient intraperitoneal regimen for epithelial ovarian, primary peritoneal or fallopian tube cancer.
    Chemotherapy, 2013, Volume: 59, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Middle Aged; Neoplasm Staging; Neoplasms, Multiple Primary; Outpatients; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Treatment Outcome

2013
Survival and prognostic factors of patients with primary fallopian tube cancer receiving adjuvant paclitaxel and carboplatin chemotherapy.
    The journal of obstetrics and gynaecology research, 2014, Volume: 40, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Hospitals, University; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Analysis; Thailand

2014
Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer.
    American journal of obstetrics and gynecology, 2015, Volume: 212, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Genes, BRCA1; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Prognosis; Proportional Hazards Models

2015
Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Aug-01, Volume: 33, Issue:22

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Hysterectomy; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Omentum; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Predictive Value of Tests; Prognosis; Reproducibility of Results; Salpingectomy; Treatment Outcome

2015
Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).
    Gynecologic oncology, 2015, Volume: 139, Issue:2

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cohort Studies; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Severity of Illness Index; Survival Rate; Treatment Outcome

2015
Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study.
    Chinese journal of cancer, 2016, May-09, Volume: 35

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Injections, Intraperitoneal; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Propensity Score; Prospective Studies; Treatment Outcome

2016
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for gynecological malignancies: a single center experience.
    European journal of gynaecological oncology, 2016, Volume: 37, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cohort Studies; Cytoreduction Surgical Procedures; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Sarcoma; Survival Rate; Treatment Outcome; Uterine Neoplasms; Young Adult

2016
Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.
    Gynecologic oncology, 2016, Volume: 142, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Docetaxel; Fallopian Tube Neoplasms; Female; Guideline Adherence; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Taxoids

2016
Investigating the Impact of Body Mass Index on Intraperitoneal Chemotherapy Outcomes in Ovarian and Fallopian Tube Cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2016, Volume: 26, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Body Mass Index; Carboplatin; Cisplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Treatment Outcome

2016
Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancer.
    Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Analysis

2016
Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas.
    Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies

2016
Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer.
    Gynecologic oncology, 2008, Volume: 111, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Paclitaxel; Posterior Leukoencephalopathy Syndrome

2008
Paclitaxel- and platinum-based postoperative chemotherapy for primary fallopian tube carcinoma: a single institution experience.
    Oncology, 2008, Volume: 75, Issue:1-2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Platinum Compounds; Retrospective Studies; Survival Analysis; Treatment Outcome

2008
Chemotherapy consisting of paclitaxel and carboplatin benefits a patient with malignant mixed müllerian tumor of the fallopian tube.
    International journal of clinical oncology, 2008, Volume: 13, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Fallopian Tube Neoplasms; Female; Humans; Mixed Tumor, Mullerian; Ovariectomy; Paclitaxel

2008
An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
    Gynecologic oncology, 2009, Volume: 113, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Outpatients; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Retrospective Studies

2009
Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: a single institution's experience.
    Gynecologic oncology, 2009, Volume: 114, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Cisplatin; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome

2009
Primary fallopian tube carcinoma: results of a retrospective analysis of 64 patients.
    Gynecologic oncology, 2009, Volume: 115, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Treatment Outcome

2009
Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma.
    Gynecologic oncology, 2010, Volume: 116, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Databases, Factual; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epithelial Cells; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies

2010
Cancer-associated retinopathy in neuroendocrine carcinoma of the fallopian tube.
    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2010, Volume: 30, Issue:3

    Topics: Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Neuroendocrine; Fallopian Tube Neoplasms; Female; Humans; Paclitaxel; Positron-Emission Tomography; Retinal Diseases; Visual Acuity; Visual Fields

2010
Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer.
    American journal of clinical oncology, 2011, Volume: 34, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Brachytherapy; Brain Neoplasms; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Combined Modality Therapy; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Risk Factors; Survival Rate; Taxoids; Treatment Outcome

2011
A randomized Phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer.
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Japan; Ovarian Neoplasms; Paclitaxel; Patient Selection; Peritoneal Neoplasms; Randomized Controlled Trials as Topic; Research Design

2011
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-125 Antigen; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Cytotoxins; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome

2011
Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.
    Oncology reports, 2011, Volume: 25, Issue:4

    Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Immunoenzyme Techniques; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Transforming Growth Factor beta1

2011
Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome

2012
A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2010, Volume: 20, Issue:7

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Survival Rate; Treatment Outcome

2010
Primary fallopian tube carcinoma: clinicopathological analysis of 12 cases.
    Taiwanese journal of obstetrics & gynecology, 2011, Volume: 50, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Diagnosis, Differential; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Retrospective Studies

2011
Second-line chemotherapy for carboplatin/paclitaxel-refractory ovarian cancer: are multi-agent chemotherapies of little value truly?
    European journal of gynaecological oncology, 2011, Volume: 32, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids

2011
Feasibility study on biweekly paclitaxel treatment as maintenance chemotherapy in advanced müllerian carcinoma.
    Gynecologic and obstetric investigation, 2012, Volume: 73, Issue:4

    Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Endometrioid; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome

2012
Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2012, Volume: 22, Issue:4

    Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate

2012
Supplementation with hydrocortisone on the 3rd-5th day following dexamethasone premedicated chemotherapy eliminated severe dizziness and postural hypotension.
    Kardiologia polska, 2012, Volume: 70, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dexamethasone; Dizziness; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Humans; Hydrocortisone; Hypotension, Orthostatic; Middle Aged; Paclitaxel; Premedication; Time Factors

2012
Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
    Gynecologic oncology, 2012, Volume: 125, Issue:3

    Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult

2012
Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer.
    Gynecologic oncology, 2012, Volume: 126, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Kaplan-Meier Estimate; Lymph Node Excision; Middle Aged; Neoplasm Grading; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Pelvis; Peritoneal Neoplasms; Proportional Hazards Models; Retrospective Studies

2012
Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
    Gynecologic oncology, 2012, Volume: 127, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Injections, Intraperitoneal; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies

2012
Stage III malignant mixed Müllerian tumor of the fallopian tube: a case of 5-year survival after optimal debulking and adjuvant chemotherapy with paclitaxel plus carboplatin.
    Taiwanese journal of obstetrics & gynecology, 2012, Volume: 51, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Mixed Tumor, Mullerian; Paclitaxel

2012
Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2012, Volume: 22, Issue:8

    Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate

2012
Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
    Oncology, 2013, Volume: 84, Issue:3

    Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate

2013
Dose-dense paclitaxel with carboplatin for advanced ovarian cancer: a feasible treatment alternative.
    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2013, Volume: 35, Issue:1

    Topics: Alberta; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Recombinant Proteins; Survival Rate

2013
Effects of Taxol on ascites cytology from a patient with fallopian tube carcinoma: report of a case with ultrastructural studies.
    Diagnostic cytopathology, 2002, Volume: 27, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; Ascites; Cystadenocarcinoma, Serous; Fallopian Tube Neoplasms; Female; Humans; Microscopy, Electron; Middle Aged; Mitosis; Paclitaxel; Pleural Effusion

2002
Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum.
    Gynecologic oncology, 2003, Volume: 91, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carboplatin; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids

2003
Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2005, Volume: 88, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cross-Sectional Studies; Fallopian Tube Neoplasms; Female; Genital Neoplasms, Female; Hematologic Diseases; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome

2005
A pilot study of weekly docetaxel therapy for recurrent ovarian cancer, tubal cancer, and primary peritoneal cancer.
    European journal of gynaecological oncology, 2005, Volume: 26, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; CA-125 Antigen; Docetaxel; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Platinum Compounds; Taxoids; Treatment Outcome

2005
Aggressive multimodality treatment in transitional cell carcinoma of the parafallopian tube: report of 2 cases and review of the literature.
    Gynecologic oncology, 2006, Volume: 102, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel

2006
Case records of the Massachusetts General Hospital. Case 11-2006. A 54-year-old woman with a mass in the pelvis.
    The New England journal of medicine, 2006, Apr-13, Volume: 354, Issue:15

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystadenocarcinoma, Papillary; Diagnosis, Differential; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Paclitaxel; Tomography, X-Ray Computed

2006
Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Gynecologic oncology, 2008, Volume: 108, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate

2008
[Analysis of therapeutic result and prognostic factor in primary fallopian tube carcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Papillary; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Hysterectomy; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Ovariectomy; Paclitaxel; Survival Rate; Taxoids

2007
Primary fallopian tube adenocarcinoma: clinical complete response after salvage treatment with high-dose paclitaxel.
    Gynecologic oncology, 1995, Volume: 58, Issue:2

    Topics: Adenocarcinoma; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Salvage Therapy

1995
Primary carcinoma of the fallopian tube: report on two cases.
    European journal of obstetrics, gynecology, and reproductive biology, 1996, Volume: 70, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma, Papillary; CA-125 Antigen; Cisplatin; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Paclitaxel

1996
Recurrent metastatic fallopian tube carcinoma in pregnancy.
    Gynecologic oncology, 2001, Volume: 81, Issue:1

    Topics: Abdominal Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fallopian Tube Neoplasms; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Salvage Therapy

2001
Experience at the Memorial Sloan-Kettering Cancer Center with paclitaxel-based combination chemotherapy following primary cytoreductive surgery in carcinoma of the fallopian tube.
    Gynecologic oncology, 2002, Volume: 84, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fallopian Tube Neoplasms; Female; Humans; Paclitaxel

2002
[Clinical observation of palitaxel in the treatment of gynecologic malignant tumors].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2000, Volume: 22, Issue:2

    Topics: Adult; Antineoplastic Agents; Cisplatin; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome

2000
Brain metastases from fallopian tube carcinoma responsive to intra-arterial carboplatin and intravenous etoposide: a case report.
    Journal of neuro-oncology, 2001, Volume: 55, Issue:3

    Topics: Adenocarcinoma, Papillary; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brain Stem; Carboplatin; Carotid Arteries; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Dacarbazine; Etoposide; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Magnetic Resonance Imaging; Middle Aged; Paclitaxel; Physical Examination; Rupture, Spontaneous; Temozolomide; Temporal Lobe; Vertebral Artery

2001